Table 6.
Comparison of indicators in the use of rhTPO for treatment of grade II and IV thrombocytopenia [n, (%)].
| Indicators | Use of recombinant human thrombopoietin (rhTPO) | z/χ2 value | P value | |
|---|---|---|---|---|
| Grade II (n = 100) | Grade IV (n = 39) | |||
| Days of treatment | 5.00 (3.00, 6.00) | 6.00 (4.00, 11.00) | −2.955 | 0.003 |
| Time to increase platelets (days) | 3.00 (2.00, 5.00) | 6.00 (3.00, 11.00) | −4.235 | <0.001 |
| Delay of the next chemoradiotherapy cycle (days) | 0 (0, 5.75) | 3.00 (0, 8.00) | −2.235 | 0.025 |
| Prolonged hospitalization due to platelet decline (days) | 1.00 (0,6.00) | 5.00 (0,8.00) | −2.655 | 0.008 |
| Increased hospitalization costs due to platelet decline | 5040.00 (3024.00, 6979.00) | 7440.00 (5874.00, 14410.00) | −4.755 | <0.001 |
| Platelet transfusion | ||||
| No | 95 (95.0) | 16 (41.0) | 50.813 | <0.001 |
| Yes | 5 (5.0) | 23 (59.0) | ||